Managed Care

 

IgE-Blocking Therapy for Difficult-to-Treat Asthma: A Brief Review

MANAGED CARE March 2004. © MediMedia USA
Peer-Reviewed

IgE-Blocking Therapy for Difficult-to-Treat Asthma: A Brief Review

Omalizumab, a novel therapy that targets specific steps in the inflammatory cascade of asthma, may benefit the hard-to-treat patient.
Gailen D. Marshall Jr., MD, PhD
University of Texas Health Science Center at Houston Medical School
MANAGED CARE March 2004. ©MediMedia USA

Omalizumab, a novel therapy that targets specific steps in the inflammatory cascade of asthma, may benefit the hard-to-treat patient.

Gailen D. Marshall Jr., MD, PhD

University of Texas Health Science Center at Houston Medical School

Christine A. Sorkness, PharmD

University of Wisconsin, Schools of Pharmacy and Medicine

ABSTRACT

Purpose. To review the characteristics of difficult-to-treat asthma and describe patients who may benefit from therapy with the recently approved humanized monoclonal anti-immunoglobulin E (IgE) antibody, omalizumab.

Principal findings. Up to 20 percent of patients have difficult-to-treat asthma. These patients consume a disproportionate share of asthma care resources. Clinical and economic outcomes can be improved via improved self-management, increased adherence to prescribed therapy, and better compliance to national asthma treatment guidelines. These patients also may benefit from therapies that directly target mechanisms responsible for persistent airway inflammation and elicit favorable clinical responses.

Conclusions. Effective asthma control remains difficult in a small cohort of patients with persistent, severe airway inflammation. Management strategies that improve asthma control and reduce exacerbations can improve clinical outcomes and minimize health care resource utilization.

Key Words: asthma, asthma management, immunoglobulin E, IgE blockers, omalizumab

Author correspondence:
Gailen D. Marshall Jr., MD, PhD
Professor and Director
Division of Allergy and Clinical Immunology
The University of Texas Health Science Center
6431 Fannin 4.202 MSB
Houston, TX 77030
Email: gmarshall@uth.tmc.edu

Research supported by Genentech Inc. and Novartis Pharmaceutical Corp.

This paper has undergone peer review by appropriate members of Managed Care's Editorial Advisory Board.

Meetings

4th Partnering With ACOs Summit Los Angeles, CA October 27–28, 2014
PCMH & Shared Savings ACO Leadership Summit Nashville, TN November 3–4, 2014
2014 Annual HEDIS® and Star Ratings Symposium Nashville, TN November 3–4, 2014
Medicare Risk Adjustment, Revenue Management, & Star Ratings Fort Lauderdale, FL November 12–14, 2014
World Orphan Drug Congress Europe 2014 Brussels, Belgium November 12–14, 2014
Healthcare Chief Medical Officer Forum Alexandria, VA November 13–14, 2014
Home Care Leadership Summit Atlanta, GA November 17–18, 2014
HealthIMPACT Southeast Tampa, FL January 23, 2015